                               SEQUENCE LISTING

<110> BICYCLERD LIMITED
 
<120> BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE MOIETIES AND USES 
      THEREOF

<130> BIC-C-P2387PCT

<140>
<141>

<150> 62/594,613
<151> 2017-12-05

<150> 62/524,721
<151> 2017-06-26

<160> 8     

<170> PatentIn version 3.5

<210> 1
<211> 26
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (1)..(1)
<223> Beta-Ala

<220>
<221> MOD_RES
<222> (2)..(11)
<223> Sarcosine

<220>
<221> MOD_RES
<222> (14)..(14)
<223> D-Ala

<220>
<221> MOD_RES
<222> (17)..(17)
<223> 1Nal

<220>
<221> MOD_RES
<222> (18)..(18)
<223> D-Ala 

<220>
<221> MOD_RES
<222> (25)..(25)
<223> tBuGly


<400> 1
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Ala Cys Xaa Asn Glu 
1               5                   10                  15      


Xaa Xaa Cys Glu Asp Phe Tyr Asp Xaa Cys 
            20                  25      


<210> 2
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (2)..(2)
<223> D-Ala 

<220>
<221> MOD_RES
<222> (5)..(5)
<223> 1Nal

<220>
<221> MOD_RES
<222> (6)..(6)
<223> D-Ala 

<220>
<221> MOD_RES
<222> (13)..(13)
<223> tBuGly

<400> 2
Cys Xaa Asn Glu Xaa Xaa Cys Glu Asp Phe Tyr Asp Xaa Cys 
1               5                   10                  


<210> 3
<211> 24
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (1)..(1)
<223> Beta-Ala

<220>
<221> MOD_RES
<222> (2)..(11)
<223> Sarcosine

<400> 3
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Ala Cys Thr Glu Cys 
1               5                   10                  15      


Trp Val Asp Gly Trp Val Pro Cys 
            20                  


<210> 4
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 4
Cys Thr Glu Cys Trp Val Asp Gly Trp Val Pro Cys 
1               5                   10          


<210> 5
<211> 22
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> source
<223> /note="N-term Ac"

<220>
<221> MOD_RES
<222> (4)..(4)
<223> HArg

<220>
<221> MOD_RES
<222> (15)..(20)
<223> Sarcosine

<400> 5
Cys Ile Leu Xaa Pro Asn Cys Asp Leu Asp Gly Arg Cys Ala Xaa Xaa 
1               5                   10                  15      


Xaa Xaa Xaa Xaa Asp Lys 
            20          


<210> 6
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> source
<223> /note="N-term Ac"

<220>
<221> MOD_RES
<222> (4)..(4)
<223> HArg

<400> 6
Cys Ile Leu Xaa Pro Asn Cys Asp Leu Asp Gly Arg Cys Ala 
1               5                   10                  


<210> 7
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (15)..(20)
<223> Sarcosine

<220>
<221> MOD_RES
<222> (21)..(21)
<223> Fluoresceinated Lys 

<400> 7
Ala Cys Ala Glu Cys Trp Ile Asp Gly Trp Val Pro Cys Ala Xaa Xaa 
1               5                   10                  15      


Xaa Xaa Xaa Xaa Xaa 
            20      


<210> 8
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> source
<223> /note="N-term FITC-LC"

<400> 8
Gly Arg Gly Asp Ser Pro 
1               5       


